Steatogenesis in adult-onset type II citrullinemia is associated with down-regulation of PPARα

Abstract

SLC25A13 (citrin or aspartate-glutamate carrier 2) is located in the mitochondrial membrane in the liver and its genetic deficiency causes adult-onset type II citrullinemia (CTLN2). CTLN2 is one of the urea cycle disorders characterized by sudden-onset hyperammonemia due to reduced argininosuccinate synthase activity. This disorder is frequently accompanied with hepatosteatosis in the absence of obesity and ethanol consumption. However, the precise mechanism of steatogenesis remains unclear. The expression of genes associated with fatty acid (FA) and triglyceride (TG) metabolism was examined using liver samples obtained from 16 CTLN2 patients and compared with 7 healthy individuals. Although expression of hepatic genes associated with lipogenesis and TG hydrolysis was not changed, the mRNAs encoding enzymes/proteins involved in FA oxidation (carnitine palmitoyl-CoA transferase 1α, medium- and very-long-chain acyl-CoA dehydrogenases, and acyl-CoA oxidase 1), very-low-density lipoprotein secretion (microsomal TG transfer protein), and FA transport (CD36 and FA-binding protein 1), were markedly suppressed in CTLN2 patients. Serum concentrations of ketone bodies were also decreased in these patients, suggesting reduced mitochondrial β-oxidation activity. Consistent with these findings, the expression of peroxisome proliferator-activated receptor α (PPARα), a master regulator of hepatic lipid metabolism, was significantly down-regulated. Hepatic PPARα expression was inversely correlated with severity of steatosis and circulating ammonia and citrulline levels. Additionally, phosphorylation of c-Jun-N-terminal kinase was enhanced in CTLN2 livers, which was likely associated with lower hepatic PPARα. Collectively, down-regulation of PPARα is associated with steatogenesis in CTLN2 patients. These findings provide a novel link between urea cycle disorder, lipid metabolism, and PPARα.

Clinicopathological characteristics of non‐B non‐C hepatocellular carcinoma without past hepatitis B virus infection

“…Diabetes mellitus (DM) was judged as fasting blood sugar (FBS) >120 mg/dL or hemoglobin A1c (HbA1c) >6.5% after conversion into National Glycohemoglobin Standardization Program values or the use of glucose‐lowering drugs . Hyperlipidemia (HL) was diagnosed when serum total cholesterol (T‐chol) was >220 mg/dL or triglycerides (TG) were >150 mg/dL in a fasting state or the use of lipid‐lowering agents …”

“…23,24 Hyperlipidemia (HL) was diagnosed when serum total cholesterol (T-chol) was >220 mg/dL or triglycerides (TG) were >150 mg/dL in a fasting state or the use of lipid-lowering agents. 25,26…”

The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans

“…Although, sometimes, simple steatosis is alluded to as 'nonalcoholic fatty liver' it is, nevertheless, a disease which is worth treating not only to untrigger its potential progression to NASH but also to reduce the risk of [128]. Consistently, PPAR-a activation improves hepatic IR and steatosis in high-fructose-diet-fed mice [129].…”

Growth arrest and DNA damage-inducible 45α protects against nonalcoholic steatohepatitis induced by methionine- and choline-deficient diet

“…Preparation of whole liver homogenates was conducted as described previously [15–17] and their protein concentrations were measured colorimetrically with the BCA™ protein assay kit. Whole liver homogenates (30–80 μg of protein in each lane) were separated using sodium dodecyl sulfate-polyacrylamide gel electrophoresis.…”